CRISPR Therapeutics Stock Wins a Buy Rating: What You Need to Know

Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one high-profile Wall Street pick and putting it under the microscope...

CRISPR could change the world -- and Piper Jaffray is placing its bet on the company that took the name of this revolutionary gene-editing tool for its own: CRISPR Therapeutics (NASDAQ: CRSP).

This morning, Piper announced it is initiating coverage of Swiss genetics company CRISPR Therapeutics with an overweight rating and a $30 price target (shares currently cost less than $20). It's far from a sure bet, but for investors who won't balk at a big gamble on a potentially even bigger payday, it's a bet that could pay off.

Source: Fool.com